Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Article on Tubulis’ novel ADC conjugation technology P5 makes it to the cover of Chemical Science!

Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer

New Tubulis Paper in Blood highlights potential of next-generation ADC for effective & safe treatment of acute myeloid leukemia

ERP Article: Actualising the Power of Antibody-Drug Conjugates as Cancer Therapeutics

Tubulis moves into the Innovation and Startup Center for Biotechnology IZB in Martinsried

Tubulis Welcomes Mary Ann Lumiqued as Vice President Program Management

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Olivier Marcq Joins Tubulis as Vice President CMC

Tubulis Publishes Deep-dive into Proprietary P5-Conjugation Technology in European Journal of Organic Chemistry

Tubulis Welcomes Magdalena Zikmundova as Associate Medical Director and Armin Weidmann as Vice President Quality

Tubulis Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts

Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory Board

Tubulis appoints Günter Fingerle-Rowson as Chief Medical Officer to lead the clinical development of its new generation of ADCs

Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

Tubulis and Glycotope announce research and feasibility agreement for the discovery of antibody drug conjugates

Tubulis awarded at Venture.Med 2019